<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990325</url>
  </required_header>
  <id_info>
    <org_study_id>ABX464-005</org_study_id>
    <nct_id>NCT02990325</nct_id>
  </id_info>
  <brief_title>A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults</brief_title>
  <official_title>An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abivax S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abivax S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological&#xD;
      sequelae associated with exposure to ABX464 and to explore selected immunological endpoints,&#xD;
      compartmental pharmacokinetics, and pharmacodynamics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological&#xD;
      sequelae associated with exposure to ABX464 and to explore selected immunological endpoints,&#xD;
      compartmental pharmacokinetics, and pharmacodynamics. The site will screen and enroll 12&#xD;
      HIV-infected subjects who will receive 150 mg ABX464 orally once daily for 28 days (Cohort&#xD;
      1). Following completion of this cohort a further 24 subjects will be enrolled: 12&#xD;
      HIV-uninfected subjects will receive 50 mg ABX464 orally once daily for 28 days (Cohort 2)&#xD;
      and 12 HIV-infected subjects (Cohort 3) who will 50 mg ABX464 orally once daily for 84 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of ABX464 and its main Metabolite in sera and in rectal tissue</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>Pharmacokinetic parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA copies/ml</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>Viral Load Assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ and CD8+ counts (Cell/mm3)</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>T-cell determinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total HIV-1 DNA reservoir in PBMC and rectal tissue</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>HIV reservoir cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota characterization using deep sequencing</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>Microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation markers in cellular populations (CD3, CD8, CD4, CD45RA, CCR7, CD27, CD28, CD38, HLA-DR, PD-1)</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>T-cell function determinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Up to 112 days after first study treatment administration</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV Infections</condition>
  <condition>Health Volunteers</condition>
  <arm_group>
    <arm_group_label>ABX464 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABX464, 50mg per Capsule Three Capsules per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABX464 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABX464, 50mg per Capsule One Capsule per day for 28 or 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464 150mg</intervention_name>
    <description>ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)</description>
    <arm_group_label>ABX464 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464 50mg</intervention_name>
    <description>ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects) or from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)</description>
    <arm_group_label>ABX464 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Males aged 18-65 years;&#xD;
&#xD;
          -  Subjects with adequate hematological and biochemical laboratory parameters&#xD;
&#xD;
          -  Subjects should be able and willing to comply with study visits and procedures as per&#xD;
             protocol;&#xD;
&#xD;
          -  Subjects should understand, sign and date the written voluntary informed consent form&#xD;
             at the screening visit prior to any protocol-specific procedures being performed;&#xD;
&#xD;
          -  Subjects must agree to use in addition to the condom, a second highly effective method&#xD;
             (one for the subject and one for the partner) of contraception (defined as per the&#xD;
             CTFG Guidance).&#xD;
&#xD;
        For HIV positive Subjects&#xD;
&#xD;
          -  Subjects with a positive HIV-1 serology at any time before the study entry.&#xD;
&#xD;
          -  Subjects treated for at least 12 months prior to screening with Dolutegravir or&#xD;
             Raltegravir combined with either Tenofovir + Emtricitabine (TDF/FTC) or Abacavir +&#xD;
             Lamivudine (ABC/3TC);&#xD;
&#xD;
          -  Subjects with HIV plasma viral load ≤ 50 copies/mL during the 6 months prior to&#xD;
             screening with a maximum of 2 blips ≤ 1000 copies during this period;&#xD;
&#xD;
          -  Subjects' HIV-1 plasma viral load to be ≤ 100,000 copies/mL at any time beyond 6&#xD;
             months after the estimated date of primary infection;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic disease, anaphylaxis or reactions likely to be triggered or&#xD;
             exacerbated by any component of investigational products;&#xD;
&#xD;
          -  Acute or chronic infectious disease other than HIV infection (include but not limited&#xD;
             to viral hepatitis such as hepatitis B, hepatitis C, active tuberculosis, active&#xD;
             syphilis [i.e. currently treated], HTLV-1, HTLV-2).&#xD;
&#xD;
          -  Acute, chronic or history of clinically relevant pulmonary, cardiovascular,&#xD;
             gastrointestinal, hepatic, pancreatic or renal functional abnormality, encephalopathy,&#xD;
             neuropathy or unstable CNS pathology, angina or cardiac arrhythmias, or any other&#xD;
             clinically significant medical problems as determined by physical examination and/or&#xD;
             laboratory screening tests and/or medical history;&#xD;
&#xD;
          -  Severe hepatic impairment;&#xD;
&#xD;
          -  Acute, chronic or history of immunodeficiency or autoimmune disease other than HIV&#xD;
             infection;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul GINESTE, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abivax S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Catalogna</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABX464, HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

